To further examine the involvement of hepatic NPC1L1 in steatosis formation (Figure 1), we next administered the NPC1L1‐selective inhibitor ezetimibe to L1‐Tg mice for 2 weeks by mixing it in the mouse feed. The gene discussed is NPC1L1; the disease is steatosis.